LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the Company or Second Sight), a leading developer of implantable visual prostheses that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health (NIH) of the release of year four funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the Orion Trial), grant 5UH3NS103442. The NIH released $1.1 million of the $6.4 million planned five-year grant. The Company uses the funds primarily to pay UCLA and Baylor College of Medicine to conduct the Orion Trial. The funding supports continuation of this important research and testing of the Orion Visual Cortical Prosthesis.
About the Orion Visual Cortical Prosthesis System
Leveraging Second Sights 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brains visual cortex, where it is intended to provide the perception of patterns of light. An early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system.
About Second Sight Medical Products, Inc.
Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prostheses that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Companys headquarters are in Los Angeles, California. More information is available at secondsight.com. On February 4, 2022, Second Sight entered into a merger agreement with Nano Precision Medical, Inc. (NPM), and, following approval by shareholders of the Company, anticipates concluding the merger in August 2022.
Safe Harbor
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: target, believe, expect, will, may, anticipate, estimate, would, positioned, future, intended and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Examples of forward-looking statements include, among others, statements made in this press release regarding the amount of NIH grant proceeds expected to be received. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Second Sights current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) legal claims or proceedings relating to Second Sights termination of the Memorandum of Understanding with Pixium Vision and costs relating thereto; (2) changes in applicable laws or regulations; (3) the possibility that Second Sight may be adversely affected by other economic, business, and/or competitive factors; (4) the impact of COVID-19 on Second Sights business; (5) the possibility that shareholders of the Company may not approve the merger with NPM or that the merger may not be completed for any other reason; and (6) various other risks and uncertainties. Some of these risks and uncertainties may in the future be amplified by the COVID-19 outbreak, including subvariants thereof and there may be additional risks that Second Sight considers immaterial or which are unknown. A further list and description of risks and uncertainties can be found in Second Sights Annual Report on Form 10-K filed on March 29, 2022, and in the Companys Forms 10-K/A filed on May 2, 2022, S-4 filed on May 13, 2022, and 10-Q filed on May 16, 2022, and as thereafter amended. Any forward-looking statement made by us in this press release is based only on information currently available to Second Sight and speaks only as of the date on which it is made. Second Sight undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
Additional Information and Where to Find It
This communication, among other things, relates to a proposed business combination of the Company and NPM. The Company filed the registration statement on Form S-4 with the Securities and Exchange Commission (the SEC), which included a document that serves as a prospectus and proxy statement of the Company. The SEC declared the registration statement effective on June 24, 2022, and the proxy statement/prospectus was first mailed to shareholders of the Company on or about June 29, 2022. The proxy statement/prospectus described above contains important information about the Company, NPM, proposed merger, and related matters. This communication is not a substitute for the proxy statement/prospectus described above. Investors and securityholders are urged to carefully read the proxy statement/prospectus and all other relevant documents filed by the Company with the SEC because they contain important information about the merger and related matters. All documents are available free of charge at the SECs website (www.sec.gov). You may also obtain these documents by contacting Companys Investor Relations department at investors@secondsight.com.
Participants of Solicitation
The Company and its respective directors and executive officers may be deemed to be participants in any solicitation of proxies in connection with the proposed merger. Information about the Companys directors and executive officers is available in the Companys Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2021. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the proxy statement/prospectus and all other relevant materials filed with the SEC regarding the proposed merger when they become available. This document is available from the Company free of charge as described in the preceding paragraph.
Read more here:
Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study - Business Wire
- Nano Medicine: Meaning, Advantages and Disadvantages - BioTechnology Notes - December 18th, 2022
- www.the-scientist.com - December 18th, 2022
- Applications of Nanotechnology - National Nanotechnology Initiative - December 18th, 2022
- Nanotechnology Timeline | National Nanotechnology Initiative - October 29th, 2022
- Nano based drug delivery systems: recent developments and future ... - October 21st, 2022
- The Application of Nanotechnology and Nanomaterials in Cancer Diagnosis and Treatment: A Review - Cureus - September 16th, 2022
- 'Glass bubble' nanocarrier boosts effects of combination therapy for pancreatic cancer - UCLA Newsroom - September 16th, 2022
- International Conference (Sep. 15-17) on Advances in Molecular Diagnostics and Precision Medicine (AMDP-2022.. - ETHealthWorld - September 16th, 2022
- Reebok Nano X2 Adventure Review: A Wild Way to Log Your Workouts - Gear Patrol - August 30th, 2022
- PhD within Particle Engineering job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 306487 - Times Higher Education - August 30th, 2022
- Nanoparticles' Role in Eliminating Cancer Cells - MedTech Outlook - August 22nd, 2022
- The first female astronaut from a North African nation will be a Tunisian military aviator - Atalayar - August 22nd, 2022
- Fast and noninvasive electronic nose for sniffing out COVID-19 based on exhaled breath-print recognition | npj Digital Medicine - Nature.com - August 22nd, 2022
- Reebok's Nano X2 Adventure Helps You Take Your Workouts Anywhere - Gear Patrol - August 14th, 2022
- How Houston's nonprofit funds early research that leads to breakthroughs like the COVID vaccine - Houston Chronicle - August 14th, 2022
- Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma's Nano-in and No-Pass Mimic Nanoparticle Technologies in Anti-Aging and... - July 27th, 2022
- Nanorobots Market to close to USD 19576.43 million with CAGR of 12.23% during the forecast period to 2029 - Digital Journal - July 27th, 2022
- Aviceda Therapeutics Announces Key Opinion Leader in Ophthalmology Drug Development Tarek S. Hassan, MD to Join Management Team as Chief Development... - July 27th, 2022
- Columbia Business School and Columbia Engineering to Offer New "Dual MBA/Executive MS in Engineering and Applied Science" Program - Yahoo... - July 19th, 2022
- Internet of Nano Things Market is Poised to Grow at a CAGR of 24.12% during the Forecast Period of 2022-2031 - Digital Journal - July 11th, 2022
- Notable Thermal and Mechanical Properties of New Hybrid Nanostructures - AZoM - July 11th, 2022
- Eggshell and bioceramics: Break an egg to fix a tooth or two - BusinessLine - July 11th, 2022
- Nanomedicine in Central Nervous System Injury and Repair Market Share, Regional Growth Analysis, Upcoming Trends, Growth Factors and Leading... - July 11th, 2022
- Nanorobotics Market 2022 Research Report Analysis from Perspective of Segmentation and Industry Growth 2030 Designer Women - Designer Women - July 11th, 2022
- Artificial Intelligence in Medical Diagnostics Market Worth $9.38 Billion by 2029 - Exclusive Report by Meticulous Research - GlobeNewswire - July 11th, 2022
- $2.38M to test nano-engineered brain cancer treatment in mice - University of Michigan News - June 22nd, 2022
- New Amrita Hospital is all set to open in Faridabad in August this year; 2,400-bed facility will become Indias biggest private hospital - The... - June 22nd, 2022
- Global Advanced Functional Materials Market To Be Driven By The Surging Demand From Medical Sector In The Forecast Period Of 2021-2026 Designer Women... - June 22nd, 2022
- An effective nano drug delivery and combination therapy for the treatment of Tuberculosis | Scientific Reports - Nature.com - June 13th, 2022
- Nanotechnology is poised to shape the future of Healthcare - ETHealthWorld - June 4th, 2022
- New Silence ALS Initiative is Giving Hope to Nano-Rare Patients - BioSpace - June 4th, 2022
- Nanotechnology in the Global Medical Applications Market 2022, Featuring Profiles of Abbott, Abraxis Bioscience, Elan, Orthovita, EyePoint... - May 15th, 2022
- Nano state: tiny and now everywhere, how big a problem are nanoparticles? - The Guardian - May 2nd, 2022
- Nanomedicine Market to 2030 Insights and Forecast with Impact of COVID-19 | Abbott Laboratories, DiaSorin S.p.A, Invitae Corporation, Mallinckrodt... - May 2nd, 2022
- Cancer and Nanotechnology - National Cancer Institute - April 19th, 2022
- Nanobots/Nanorobots Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2028 - Digital Journal - April 19th, 2022
- ERDC researchers analyze resilience in nanotechnology supply chains - erdc.usace.army.mil - April 19th, 2022
- Nano Products Online Store | Nanoproducts, Nanoparticles ... - April 6th, 2022
- The Conrad Prebys Foundation to Support the Discovery and Development of Personalized ASO Medicines for Nano-rare Patients - Business Wire - March 25th, 2022
- Space the next frontier for cancer treatment? - Australian Jewish News - March 25th, 2022
- ViaCyte Strengthens Management Team with Appointment of Alyssa Levin as Chief Financial Officer and Addition of Lisa Porter, MD, to the Board of... - January 20th, 2022
- Surface Modification and Size Contribute to Nanoplastic Toxicity - AZoNano - January 20th, 2022
- Frontiers | Nanomedicine: Principles, Properties, and ... - January 5th, 2022
- Nanotechnology In Medicine: Huge Potential, But What Are ... - January 5th, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - January 5th, 2022
- 2009 show based on conspiracy theories is shared as proof of WHO working on COVID-19 vaccines to create permanent sterility - Factly - January 5th, 2022
- How to Improve Infectious Diseases with Nanotechnology - CIO Applications - January 5th, 2022
- Biodistribution of sphingolipid nanoemulsions with 68Ga | IJN - Dove Medical Press - August 31st, 2021
- Matrix Meats Adds to Team as Interest in Cultivated Meat Grows - PRNewswire - July 21st, 2021
- Nanomedicine in Central Nervous System Injury and Repair Market Report- Trends Key Programs Analysis and Competitive Landscape Analysis The Manomet... - June 23rd, 2021
- Nanomedicine is transforming healthcare innovation - Korea IT Times - June 6th, 2021
- The Future of Cancer Treatment Using Nanotechnology - AZoNano - June 6th, 2021
- Thomas Jefferson Awards Highlight Research and Service to the University - UVA Today - June 6th, 2021
- Global Nanobots Market 2020 | Research Report Covers | (COVID-19 Analysis) | Industry Research, Drivers, Top Trends | Global Analysis And Forecast to... - October 31st, 2020
- Nanox Signs With Ambra Health to Enable Image Access and Transfer with US Hospitals and Medical imaging Providers - BioSpace - October 31st, 2020
- Global Nano Therapy Market- Industry Analysis and Forecast (2020-2027) - Stock Market Vista - October 29th, 2020
- What is Nanoscience? | Outlook and How to Invest | INN - Investing News Network - September 23rd, 2020
- Interview: The NDB team on its revolutionary nano-diamond batteries - New Atlas - August 29th, 2020
- Opportunities in the World Nanotechnology Market to 2025 - Application of Nanotechnology in Wastewater Treatment and Enhanced Renewable Energy Driving... - August 12th, 2020
- Cellics Therapeutics Announces the Publication of Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity in Nano Letters - BioSpace - June 17th, 2020
- Nanocellulose Market to Reach USD 1.08 Billion by 2027 | CAGR:20.4% | Reports And Data - PRNewswire - June 17th, 2020
- Coronavirus threat to global Healthcare Nanotechnology (Nanomedicine) Market 2020 Industry Share, Size, Consumption, Growth, Top Manufacturers, Type... - June 15th, 2020
- Kanazawa University Research: Cell Removal as the Result of a Mechanical Instability - PR Newswire UK - June 15th, 2020
- Impact of Covid-19 on Nano Chemotherapy Market is Expected to Grow at an active CAGR by Forecast to 2026 | Top Players Dell Wyse, IBM, Microsoft -... - June 15th, 2020
- Evergreen Medical Acupuncture is now offering its own supplement and herbal products, Dr. Ficks Functional Farmacy! - TippNews DAILY - June 10th, 2020
- Inolife is going to revolutionize how we take our medicine - BNNBloomberg.ca - May 24th, 2020
- Recent Progress and Future Directions: The Nano-Drug Delivery System f | IJN - Dove Medical Press - May 10th, 2020
- The future of medicine - Switzer Financial News - May 10th, 2020
- All your questions about how to wear a face mask -- answered - Action News Now - April 26th, 2020
- Edited Transcript of NANO earnings conference call or presentation 6-Feb-20 9:30pm GMT - Yahoo Finance - February 11th, 2020
- Kanazawa University Research: Combined Drug Treatment for Lung Cancer and Secondary Tumors - Yahoo Finance - February 11th, 2020
- Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors - BioSpace - February 11th, 2020
- Nano Medicine: Meaning, Advantages and Disadvantages - February 6th, 2020
- The Future Of Nano Medicine - February 6th, 2020
- VVUS Stock Jumps 70% on FDA Nod for New Formulation of Pancreaze - MicroSmallCap - February 6th, 2020
- Is the Lieber Arrest Linked to Military Brain Research and China? - Bryen's Blog - February 6th, 2020
- A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN - Dove Medical Press - January 10th, 2020
- Examine Triple Negative Breast Cancer Treatment Market expected to reach US$ 720 mn by 2026 - WhaTech Technology and Markets News - January 10th, 2020
- Triple Negative Breast Cancer Treatment Market Combining Therapies - Communal News - January 10th, 2020
- Our top 20 features of 2019 - COVER - January 5th, 2020